Cogent Biosciences Appoints James P. Geygan as Independent Director

On January 17, 2025, Cogent Biosciences (NASDAQ:COGT) announced in an 8-K filing that its Board of Directors has expanded from six to seven members with the appointment of James P. Geygan as an independent director. Mr. Geygan, age 36, will retain this position until the next annual meeting of stockholders or until his successor is duly elected, or in case of resignation, removal, or demise.

Prior to this role, Mr. Geygan has been serving as the Interim Chief Executive Officer and President of Global Value Investment Corporation (GVIC) since May 2024, an investment firm focusing on disciplined, value-oriented investing and holding a substantial stake in Cogent Biosciences. He has held various senior positions within GVIC since May 2017, contributing to the growth of GVIC’s assets under management from $84 million in December 2016 to $194 million by December 2024. With a Bachelor of Science in political science from the University of Wisconsin, Madison, Mr. Geygan brings corporate governance and capital markets expertise to the Cogent Biosciences Board.

Under the terms of his appointment, Mr. Geygan will receive a quarterly cash fee of $10,000 and 10,000 restricted stock units (RSUs) that will vest in three equal annual installments, commencing from the first anniversary of the grant date, with potential for accelerated vesting under certain conditions. In addition, he will be eligible for additional RSUs with a grant date value of $75,000 each year, coinciding with the annual stockholder meetings.

Furthermore, an indemnification agreement has been executed between the Company and Mr. Geygan, ensuring the advance payment of expenses and indemnification to the fullest extent permitted under Delaware General Corporation Law. No undisclosed arrangements or understandings led to Mr. Geygan’s appointment as a director, and there are no reportable related party transactions involving him as per Regulation S-K.

Cogent Biosciences, a company dedicated to developing precision therapies for genetically driven diseases, expands its leadership team with the addition of James P. Geygan, enhancing its strategic direction and governance structure.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cogent Biosciences’s 8K filing here.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.